Legumain inhibitor prevents breast cancer bone metastasis by attenuating osteoclast differentiation and function

Chen, Jun Song; Xu, Wenke; Song, Kaiyuan; Da, Lin-Tai; Zhang, Xin; Lin, Mengyao; Hong, Xi; Zhang, Sheng; Guo, Fang

doi:10.1016/j.bone.2023.116680

Cited by 4 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, an ATPdependent transporter protein called ABCC5 also mediates osteoclast-mediated bone resorption in breast cancer bone metastases (163). Inhibition of AEPase activity in breast cancer cells reduces osteoclast differentiation while attenuating osteolytic lesions caused by breast cancer bone metastases from breast cancer (164). Furthermore, early growth response-1 (EGR1) plays a direct role in the regulation of angiogenesis and osteoclastogenic factors in prostate cancer bone metastasis (165).…”

Section: Osteoclastsmentioning

confidence: 99%

Multiple influence of immune cells in the bone metastatic cancer microenvironment on tumors

Chen,

Lei,

Mou

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Bone is a common organ for solid tumor metastasis. Malignant bone tumor becomes insensitive to systemic therapy after colonization, followed by poor prognosis and high relapse rate. Immune and bone cells in situ constitute a unique immune microenvironment, which plays a crucial role in the context of bone metastasis. This review firstly focuses on lymphatic cells in bone metastatic cancer, including their function in tumor dissemination, invasion, growth and possible cytotoxicity-induced eradication. Subsequently, we examine myeloid cells, namely macrophages, myeloid-derived suppressor cells, dendritic cells, and megakaryocytes, evaluating their interaction with cytotoxic T lymphocytes and contribution to bone metastasis. As important components of skeletal tissue, osteoclasts and osteoblasts derived from bone marrow stromal cells, engaging in ‘vicious cycle’ accelerate osteolytic bone metastasis. We also explain the concept tumor dormancy and investigate underlying role of immune microenvironment on it. Additionally, a thorough review of emerging treatments for bone metastatic malignancy in clinical research, especially immunotherapy, is presented, indicating current challenges and opportunities in research and development of bone metastasis therapies.

show abstract

Section: Osteoclastsmentioning

confidence: 99%